Jagsonpal Pharmaceuticals Ltd
Recommendation of Dividend for the Financial Year ended March 31, 2026
DIVIDEND
● No Immediate Change
LOW RISK
📅 Filed on BSE: 27 Apr 2026, 07:43 PM IST · BSE ID: 2ed875cb-f759-42b8-85dd-e77fd7252350
View Original BSE Filing (PDF)
💡
In Simple Terms
The company's board approved paying dividends to shareholders for 2025-26, but the exact amount will be announced later.
🤖 AI Summary
- Board recommends dividend for FY26 — quantum and terms to be announced separately
- Dividend subject to shareholder approval at forthcoming Annual General Meeting
- Record date and payment schedule to follow once quantum is finalized
- No dividend amount disclosed in this filing — awaiting formal recommendation completion
🔢 Key Numbers — exact figures from BSE filing, not rounded
Dividend Status
Recommended for FY26 — quantum pending
🏢 How This Affects the Company
Dividend payout reduces retained earnings and cash available for reinvestment or debt repayment. Exact impact magnitude depends on quantum to be disclosed in follow-up announcement.
👥 What This Means For Shareholders
✅
Action Required
Shareholders must approve dividend at the AGM; no action required until record date is announced in follow-up filing.
👤
Who Is Affected
All equity shareholders holding shares as of the record date (to be announced) are eligible. Exact per-share payout amount pending disclosure.
🔍
Management Signal
Board confirmation of dividend indicates operating cash generation and shareholder-friendly capital allocation during FY26.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Follow-up filing with dividend quantum, record date, and ex-date announcement within 10-15 days
AGM notice and approval outcome — check shareholder voting results on dividend resolution
Record date announcement — ensure shares held in demat before this date to receive dividend
LOW RISK
Dividend recommendation is routine capital allocation decision. Quantum disclosure pending does not materially alter risk profile.
💡 Investor Takeaway
Jagsonpal Pharmaceuticals Board has formally recommended FY26 dividend, confirming cash generation. However, dividend amount, payment date, and record date remain undisclosed. Investors must await separate announcement for quantum before assessing yield and ex-date implications.
⚖️ Strengths & Concerns
⚠️ Concerns
- Dividend quantum not specified in recommendation — investors lack clarity on payout size and yield impact
- Filing provides no detail on dividend policy, payout ratio, or sustainability — quantum remains pending disclosure
📅 Company Track Record
Jagsonpal Pharmaceuticals filed the same dividend recommendation category on 2026-04-27 (same date), indicating continuation of disclosure process for FY26 payout.
Based on publicly available historical data. For context only.